Emcutix Biopharmaceuticals honoured at India Leadership Conclave 2025 for redefining dermatology with integrity and innovation
Recognition underscores Emcutix’s disruptive vision in cosmetic dermatology and patient-centric skin science
Emcutix Biopharmaceuticals Ltd Honoured With “Ethical Innovation in Cosmetic Dermatology – Skin Science Disruptor Leadership 2025” at the 14th Annual India Leadership Conclave & Power Brand Awards 2025 Emcutix Biopharmaceuticals Limited, a wholly-owned subsidiary of Emcure Pharmaceuticals, has been conferred with the prestigious recognition of Ethical Innovation in Cosmetic Dermatology – Skin Science Disruptor Leadership 2025 at the 14th Annual India Leadership Conclave & Power Brand Awards 2025, held at Hotel Mumbai International Airport, Mumbai. 
The Award demonstrates Emcutix Biopharmaceuticals Ltd’s unwavering commitment to ethical innovation, scientific excellence, and patient-centric dermatology. It underscores the company’s role as a disruptor in skin science, redefining standards of care while balancing medical integrity with aesthetic advancement. By receiving this recognition at the India Leadership Conclave, Emcutix has reinforced its position as a trusted leader that not only delivers breakthrough solutions but also champions transparency, responsibility, and long-term impact in the healthcare ecosystem.
Speaking on this, Mr. G. Sathya Narayanan, CEO, Emcutix Biopharmaceuticals Limited said “This award is a powerful validation of our mission to transform dermatology in India through ethical innovation and science-driven solutions. At Emcutix, we are committed to building trust with patients and practitioners alike, while pioneering advancements that redefine skin health for the future”.
The glittering ceremony, attended by over 250 distinguished industry leaders, policymakers, and visionaries, witnessed the presentation of the coveted awards by Padma Shri Dr. Mukesh Batra, Founder & Chairman Emeritus of Dr Batra’s Healthcare, alongside Dr. Satya Brahma, Founder & Chairman of India Leadership Conclave and Editorial Head of Network 7 Media Group. Emcutix Biopharmaceuticals – Transforming Dermatology in India Founded in October 2024, Emcutix Biopharmaceuticals Limited was established with a bold vision: to transform dermatology in India through science, innovation, and patient-focused care. The company is spearheaded by Mr. G. Sathya Narayanan, former Managing Director of Galderma South Asia, who brings over 35 years of experience across pharmaceuticals and consumer healthcare. Under his leadership, Emcutix has set an ambitious target to rank among the top 10 dermatology companies in India within five years. Exclusively dedicated to dermatology, Emcutix addresses both medical and aesthetic segments, while also engaging with select pediatric practitioners. Its seasoned dermatology team is building a strong foundation across four strategic business verticals:
- Rx (Prescription): Advanced, science-driven therapies for dermatological disorders.
- Cx (Consumer): Dermatologist-endorsed skincare products for everyday use.
- Ax (Aesthetic): High-performance solutions and devices for aesthetic dermatology.
- Bx (Biologics): Next-generation biologic innovations for skin health.
Innovation Partnerships Driving Growth In line with its innovation-driven approach, Emcutix has forged strategic collaborations to bring cutting-edge dermatology solutions to India:
- UREADERM – Developed in collaboration with Canada-based Mantra Pharma, this dual-strength moisturizer powered by MLFAE technology delivers sustained 72-hour hydration, setting new benchmarks in therapeutic skincare.
- PRX Plus – Through a marketing and distribution partnership with WiQo of Italy, Emcutix introduced India’s first needle-free skin booster, a breakthrough aesthetic dermatology solution already gaining strong acceptance among leading dermatologists nationwide.
Financial Momentum & Market Traction Within its first year of operations, Emcutix is projected to close FY 2025–26 at ₹65 crore, with a target of ₹100 crore in FY 2026–27. This trajectory reflects the company’s strong market traction, strategic momentum, and unwavering commitment to innovation. Celebrating Leadership & Ethical Innovation Speaking at the conclave, Dr. Satya Brahma emphasized the importance of ethical innovation in healthcare: “The Power Brand Awards are not just about celebrating success—they are about recognizing leaders who disrupt industries with integrity, innovation, and impact. Emcutix Biopharmaceuticals embodies this spirit by redefining dermatology in India with science and ethics at its core.” Padma Shri Dr. Mukesh Batra added: “Dermatology is evolving rapidly, and companies like Emcutix are setting new standards by combining patient-centric care with breakthrough innovation. This recognition is well-deserved.” About Emcutix Biopharmaceuticals Limited Emcutix Biopharmaceuticals Limited is a wholly-owned subsidiary of Emcure Pharmaceuticals, dedicated exclusively to dermatology. With a focus on medical, aesthetic, consumer, and biologic innovations, Emcutix is committed to transforming skin science in India. Guided by visionary leadership and strategic collaborations, the company is innovating today to redefine the future of dermatology. Instituted in 2009, the ILC Power Brand Awards have evolved into a global benchmark for leadership recognition, celebrated for their robust and transparent selection process. Conceptualized by Dr. Satya Brahma, the conclave has consistently spotlighted transformative leaders who embody innovation, integrity, and impact—making the 2025 edition a resounding success.
